businesspress24.com - Questcor Pharmaceuticals, Inc. (QCOR) Investor Lawsuit Over Alleged False and Misleading Statements
 

Questcor Pharmaceuticals, Inc. (QCOR) Investor Lawsuit Over Alleged False and Misleading Statements Announced by Shareholders Foundation

ID: 1156478

(firmenpresse) - SAN DIEGO, CA -- (Marketwire) -- 10/02/12 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed by an investor in Questcor Pharmaceuticals, Inc. (QCOR) shares over alleged securities laws violations by Questcor Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements regarding its injectable drug H.P. Acthar Gel.

Investors who purchased shares of Questcor Pharmaceuticals, Inc. (QCOR) have certain options and should contact the Shareholders Foundation, Inc. by e-mail at or call +1 (858) 779-1554.

The plaintiff alleges that Questcor Pharmaceuticals, Inc. and certain of its officers and directors issued between April 26, 2011 and September 21, 2012 allegedly false and misleading statements about the effectiveness of Acthar as a treatment for multiple sclerosis and nephrotic syndrome, making it allegedly impossible for shareholders to gain a meaningful or realistic understanding of the drug's prospects and market success.

On September 24, 2012, Questcor Pharmaceuticals, Inc. disclosed in a filing with the SEC that on September 21, 2012, Questcor Pharmaceuticals, Inc. became aware of a U.S. government investigation involving Questcor Pharmaceuticals' promotional practices.

Earlier Aetna Inc. said it would limit coverage of Questcor's top-selling drug, H.P. Acthar. Aetna issued a Clinical Policy Bulletin stating that based on review of medical studies Acthar was "not medically necessary" for certain conditions for which it has been prescribed and as a result Aetna would limit the coverage of H.P. Acthar.

Shares of Questcor Pharmaceuticals, Inc. dropped from as high as $50.52 on September 18, 2012 to as low as $17.75 per share on September 27, 2012.

Those who purchased shares of Questcor Pharmaceuticals, Inc., have certain options and should contact the Shareholders Foundation, Inc. by e-mail at or call +1 (858) 779-1554.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.







CONTACT:
Shareholders Foundation, Inc.
Trevor Allen
+1 (858) 779-1554

3111 Camino Del Rio North
Suite 423
San Diego, CA 92108


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Arena Pharmaceuticals and VIVUS Weight Loss Drugs the First Approved by the FDA in Over 13 Years
SOHM Announces Second Quarter 2012 Financial Results
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 02.10.2012 - 07:35 Uhr
Sprache: Deutsch
News-ID 1156478
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SAN DIEGO, CA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 157 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Questcor Pharmaceuticals, Inc. (QCOR) Investor Lawsuit Over Alleged False and Misleading Statements Announced by Shareholders Foundation
"
steht unter der journalistisch-redaktionellen Verantwortung von

Shareholders Foundation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Shareholders Foundation



 

Who is online

All members: 10 567
Register today: 2
Register yesterday: 0
Members online: 0
Guests online: 84


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.